Conceptual approaches to modulating antibody effector functions and circulation half-life
KO Saunders - Frontiers in immunology, 2019 - frontiersin.org
Antibodies and Fc-fusion antibody-like proteins have become successful biologics
developed for cancer treatment, passive immunity against infection, addiction, and …
developed for cancer treatment, passive immunity against infection, addiction, and …
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies
Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs)
are tremendous, the design and discovery of new candidates remain a time and cost …
are tremendous, the design and discovery of new candidates remain a time and cost …
IgG Fc engineering to modulate antibody effector functions
X Wang, M Mathieu, RJ Brezski - Protein & cell, 2018 - academic.oup.com
Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An
important aspect of antibodies is their ability to bind antigen while at the same time recruit …
important aspect of antibodies is their ability to bind antigen while at the same time recruit …
Considerations for the design of antibody-based therapeutics
Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …
Current progress in innovative engineered antibodies
WR Strohl - Protein & cell, 2018 - academic.oup.com
Abstract As of May 1, 2017, 74 antibody-based molecules have been approved by a
regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based …
regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based …
FcγR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy
T cells play critical roles in anti-tumor immunity. Up-regulation of immune checkpoint
molecules (PD-1, PD-L1, CTLA-4, TIM-3, Lag-3, TIGIT, CD73, VISTA, B7-H3) in the tumor …
molecules (PD-1, PD-L1, CTLA-4, TIM-3, Lag-3, TIGIT, CD73, VISTA, B7-H3) in the tumor …
Boosting therapeutic potency of antibodies by taming Fc domain functions
Monoclonal antibodies (mAbs) are one of the most widely used drug platforms for infectious
diseases or cancer therapeutics because they selectively target pathogens, infectious cells …
diseases or cancer therapeutics because they selectively target pathogens, infectious cells …
Soluble ligands as drug targets
MM Attwood, J Jonsson, M Rask-Andersen… - Nature Reviews Drug …, 2020 - nature.com
Historically, the main classes of drug targets have been receptors, enzymes, ion channels
and transporters. However, owing largely to the rise of antibody-based therapies in the past …
and transporters. However, owing largely to the rise of antibody-based therapies in the past …
Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility
Antibodies protect from infection, underpin successful vaccines and elicit therapeutic
responses in otherwise untreatable cancers and autoimmune conditions. The human IgG2 …
responses in otherwise untreatable cancers and autoimmune conditions. The human IgG2 …
Antibody-based cancer therapy
RS Goydel, C Rader - Oncogene, 2021 - nature.com
Over the past 25 years, antibody therapeutics have emerged as clinically and commercially
successful pharmaceuticals, rapidly approaching 100 Food and Drug Administration …
successful pharmaceuticals, rapidly approaching 100 Food and Drug Administration …